Loading clinical trials...
Loading clinical trials...
A Phase II Study of Lenalidomide Following Allogeneic Stem Cell Transplant for Multiple Myeloma Patients Who Relapse or Have Disease Progression
Conditions
Interventions
lenalidomide
Locations
1
United States
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
Start Date
February 1, 2008
Primary Completion Date
August 1, 2015
Completion Date
September 1, 2015
Last Updated
May 18, 2017
NCT07523555
NCT06669247
NCT06285318
NCT07497165
NCT04973605
NCT05862012
Lead Sponsor
Fred Hutchinson Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions